Table 1.
Comparative characterization of most used viral vectors with their advantages and disadvantages for potential use in neuro-oncology.
Virus | Genome | Size, nm | Titer, transducing units in ml−1 | Capacity, thousand base pairs | Target cells | Duration of miRNA expression | Integration with recipient DNA | Transduction efficiency | Immunogenicity |
---|---|---|---|---|---|---|---|---|---|
LVs | RNA | 100 | 106–109 | 8 | Dividing cells | ↑ | + | ↑ | ↓ |
AVs | Double stranded DNA | 80–120 | 109–1013 | 20 | Dividing and non-dividing cells | ↓ | – | ↑ | ↑ |
AAVs | Single stranded DNA | 20–30 | 109–1013 | 4,5–5,0 | Dividing and non-dividing cells | ↑ | +- | ↑ | ↓ |
HSVs | Double stranded DNA | 120–300 | 108–1011 | 30–50 (up to 150 for amplicons) | Non-dividing cells | ↓ | – | ↓ | ↓ |
Abbreviations: LVs, Lentiviruses; AVs, Adenoviruses; AAVs, Adeno-associated viruses; HSVs, Herpes simplex viruses. Note: +, Possible; -, No possible; +-, Sometimes possible; ↑, High; ↓, Low.